The Infant Botulism Treatment and Prevention Program (IBTPP) is a high-visibility Departmental activity of national scope and impact because its orphan drug BabyBIG® (human Botulism Immune Globulin, licensed October 2003) has become the standard-of-care for paralyzed, critically-ill patients with infant botulism, as well as a recognized treatment for a domestic bioterrorist attack that uses botulinum toxin as a weapon. The high national profile of the program is also a consequence of its interactions with the U.S. Food and Drug Administration (FDA), the federal Centers for Disease Control and Prevention (CDC), Office of Public Health Emergency Preparedness of the U.S. Department of Health and Human Services, the Massachusetts Public Health Biologic Laboratories, the Johns Hopkins Center for Civilian Biodefense, all California local Health Departments, and approximately 200 major university, children's and community hospitals nationwide.
Our Services
Program Type
Fiscal Sponsorship
H-Medical Research
813212 Voluntary Health Organizations
Project Directory
RCE Research
Infant Botulism Prevention & Treatment
CDPH - Infant Botulism Treatment Contact Information
Stephen Arnon, Chief, Infant Botulism Treatment an (510)231-7600